PIGT
protein-codingphosphatidylinositol glycan anchor biosynthesis class T, the group of Phosphatidylinositol glycan anchor biosynthesis|Glycosylphosphatidylinositol transamidase complex|MicroRNA protein coding host genes
Gene summary
This gene encodes a protein that is involved in glycosylphosphatidylinositol (GPI)-anchor biosynthesis. The GPI-anchor is a glycolipid found on many blood cells and serves to anchor proteins to the cell surface. This protein is an essential component of the multisubunit enzyme, GPI transamidase. GPI transamidase mediates GPI anchoring in the endoplasmic reticulum, by catalyzing the transfer of fully assembled GPI units to proteins. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, May 2012]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~40.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0014165
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0014165
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0014165
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0014165
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0014165
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0014165
Submitter: ClinGen
*PIGT* was first reported in relation to autosomal recessive multiple congenital anomalies-hypotonia-seizures syndrome 3 in 2013 (Kvarnung et al., PMID: 23636107). 12 variants (missense, nonsense, frameshift, and canonical splice) that have been reported in 9 probands in 7 publications (PMIDs: 23636107, 24906948, 25943031, 28728837, 30976099, 34162574, 39417547) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by a zebrafish model and flow cytometry studies on patient cells (PMIDs: 23636107, 25943031, 28728837). In summary, there is definitive evidence supporting the relationship between *PIGT* and autosomal recessive multiple congenital anomalies-hypotonia-seizures syndrome 3. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on the meeting date August 7, 2025 (SOP Version 11).
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Genitourinary; Musculoskeletal; Neurologic; Ophthalmologic; Renal
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PIGT variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_015937.6. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 86 | 1 | 89 | ||
| missense | 11 | 185 | 16 | 1 | 213 | |
| nonsense | 4 | 1 | 1 | 6 | ||
| start loss | 0 | |||||
| frameshift | 7 | 11 | 5 | 23 | ||
| splice donor/acceptor (+/-2bp) | 1 | 1 | 1 | 3 | ||
| Total | 12 | 24 | 194 | 102 | 2 | 334 |
Highest pathogenic variant AF is 0.0001134674
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_057021.2 | 12 | MANE Select | |
| Ensembl | ENSP00000279036.6 | 12 | MANE Select | |
| RefSeq | NP_001171657.1 | 11 | Standard | |
| RefSeq | NP_001171658.1 | 11 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| pigt | Danio rerio | Structure: whole organism Quality: shortened abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Glycosylphosphatidylinositol (GPI)-anchor biosynthesis - Homo sapiens (human)
- Attachment of GPI anchor to uPAR
- Post-translational modification: synthesis of GPI-anchored proteins
- Post-translational protein modification
- Metabolism of proteins
Biological Process
- attachment of GPI anchor to protein
- neuron differentiation
- neuron apoptotic process
Molecular Function
- GPI-anchor transamidase activity
- protein binding
Cellular Component
- endoplasmic reticulum membrane
- membrane
- integral component of endoplasmic reticulum membrane
- cytoplasmic vesicle
- GPI-anchor transamidase complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000279036
- Coding exons
- 12
- Length
- 10168
- Individuals with no LoFs
- 125641
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 107
- Defined
- 125748
- p
- 0.000426
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.277 | 326 | 340 | 0.958 | 0.0000200 | 3660 |
| Missense (PolyPhen) | 145 | 158.52 | 0.9147 | 1622 | ||
| Synonymous | -1.25 | 169 | 150 | 1.13 | 0.00000870 | 1234 |
| Loss of Function | 1.78 | 19 | 29.4 | 0.646 | 0.00000158 | 306 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00025 | 0.00025 | rare |
| Latino/Admixed American | 0.00023 | 0.00023 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.0015 | 0.0014 | notable |
| Finnish | 0.00028 | 0.00028 | rare |
| European (Non-Finnish) | 0.00041 | 0.00040 | rare |
| South Asian | 0.00046 | 0.00046 | rare |
| Other | 0.00049 | 0.00049 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Component of the GPI transamidase complex. Essential for transfer of GPI to proteins, particularly for formation of carbonyl intermediates. {ECO:0000269|PubMed:11483512}.;
- Disease
- DISEASE: Multiple congenital anomalies-hypotonia-seizures syndrome 3 (MCAHS3) [MIM:615398]: An autosomal recessive syndrome characterized by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic findings including impaired vision, as well as abnormal motility of the eyes. {ECO:0000269|PubMed:23636107}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Paroxysmal nocturnal hemoglobinuria 2 (PNH2) [MIM:615399]: A disorder characterized by hemolytic anemia with hemoglobinuria, thromboses in large vessels, and a deficiency in hematopoiesis. Red blood cell breakdown with release of hemoglobin into the urine is manifested most prominently by dark-colored urine in the morning. {ECO:0000269|PubMed:23733340}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.114
Intolerance Scores
- LoFtool
- 0.941
- RVIS EVS
- -0.15
- RVIS percentile EVS
- 42.23
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- H
- Indispensability pred.
- E
- Indispensability score
- 0.832
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |